| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 27.01. | Introducing the Sunday Times Tech 100: Life sciences part 2 | ||
| 26.01. | Bausch Health hit as Xifaxan successor flunks trials | ||
| 26.01. | MSD said to have pulled back from Revolution Medicines deal | ||
| 26.01. | COPD patients will get access to Dupixent via NHS | ||
| 26.01. | Introducing the Sunday Times Tech 100: Life sciences part 1 | ||
| 23.01. | Digital osteoarthritis, bulimia tools backed for NHS use | ||
| 23.01. | Sanofi plans amlitelimab dermatitis filing after new readout | ||
| 23.01. | Corxel's raises $287m for obesity drug, and other financings | ||
| 23.01. | Change of heart as NICE backs prostate cancer drug Talzenna | ||
| 23.01. | Ovarian cancer data restores faith in Corcept's relacorilant | ||
| 22.01. | J&J says 2026 sales could top $100 billion | ||
| 22.01. | Amazon joins the AI health assistant movement | ||
| 22.01. | NICE backs Roche lupus drug that supports kidney function | ||
| 22.01. | US checks out of WHO, leaving its bill unsettled | ||
| 22.01. | 11 high-impact drugs to look out for in 2026 | ||
| 21.01. | EU approves Otsuka's long-acting HAE drug Dawnzera | ||
| 21.01. | Hopstem maps course to bring stem cell stroke therapy to US | ||
| 21.01. | ImmunityBio rises as route opens to broader Anktiva label | ||
| 21.01. | Call goes out for type 1 diabetes screening in UK | ||
| 21.01. | Data builds behind Moderna's skin cancer vaccine | ||
| 20.01. | J&J bets on Isomorphic for AI-powered drug hunt | ||
| 20.01. | ViiV ownership shifts as Pfizer sells its stake | ||
| 20.01. | Agomab and Spyglass Pharma push the IPO button | ||
| 20.01. | AstraZeneca pays $630m to get full control of AbelZeta CAR-T | ||
| 20.01. | GSK reaches $2.2bn deal to buy food allergy biotech RAPT |